HomeCompareMLGCF vs PFE

MLGCF vs PFE: Dividend Comparison 2026

MLGCF yields 1052.63% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLGCF wins by $29512389.23M in total portfolio value
10 years
MLGCF
MLGCF
● Live price
1052.63%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29512389.28M
Annual income
$24,865,533,772,207.38
Full MLGCF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MLGCF vs PFE

📍 MLGCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLGCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLGCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLGCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLGCF
Annual income on $10K today (after 15% tax)
$89,473.68/yr
After 10yr DRIP, annual income (after tax)
$21,135,703,706,376.27/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MLGCF beats the other by $21,135,703,684,056.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLGCF + PFE for your $10,000?

MLGCF: 50%PFE: 50%
100% PFE50/50100% MLGCF
Portfolio after 10yr
$14756194.67M
Annual income
$12,432,766,899,233.05/yr
Blended yield
84.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MLGCF
No analyst data
Altman Z
-6.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLGCF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLGCFPFE
Forward yield1052.63%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$29512389.28M$49.6K
Annual income after 10y$24,865,533,772,207.38$26,258.71
Total dividends collected$29159831.22M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MLGCF vs PFE ($10,000, DRIP)

YearMLGCF PortfolioMLGCF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$115,963$105,263.16$9,153$693.39+$106.8KMLGCF
2$1,264,889$1,140,808.24$8,593$849.25+$1.26MMLGCF
3$12,982,935$11,629,504.04$8,336$1,066.78+$12.97MMLGCF
4$125,449,028$111,557,287.82$8,437$1,384.80+$125.44MMLGCF
5$1,141,645,861$1,007,415,400.94$9,013$1,875.40+$1141.64MMLGCF
6$9,789,747,608$8,568,186,536.38$10,306$2,680.72+$9789.74MMLGCF
7$79,141,579,327$68,666,549,386.16$12,820$4,101.38+$79141.57MMLGCF
8$603,475,154,069$518,793,664,189.69$17,673$6,826.70+$603475.14MMLGCF
9$4,342,855,615,350$3,697,137,200,495.55$27,543$12,591.86+$4342855.59MMLGCF
10$29,512,389,280,631$24,865,533,772,207.38$49,560$26,258.71+$29512389.23MMLGCF

MLGCF vs PFE: Complete Analysis 2026

MLGCFStock

M3 Metals Corp. engages in the acquisition, exploration, and development of mineral properties in North America. The company explores for gold, copper, iron, and silver deposits. It holds interests in the Aspen gold property that includes 7 mineral claims covering an area of 4,169.81 hectares and the Stars property, which covers an area of 2,136 hectares located in the Omineca Mining Division located in north central British Columbia, Canada. The company also has interests in the Block 103 iron ore project that covers an area of 7,245 hectares located in Labrador, Canada. Additionally, it has an option agreement to acquire 100% interest in the Mohave Property located in the Mohave County, Arizona. The company was formerly known as ML Gold Corp. and changed its name to M3 Metals Corp. in July 2019. M3 Metals Corp. was incorporated in 2007 and is headquartered in West Vancouver, Canada.

Full MLGCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MLGCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLGCF vs SCHDMLGCF vs JEPIMLGCF vs OMLGCF vs KOMLGCF vs MAINMLGCF vs JNJMLGCF vs MRKMLGCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.